

Akston Biosciences, Biolexis bring room-temperature stable COVID-19 vaccine

18 March 2022 | News

Biolexis will launch AKS-452 as “AmbiVax-C” for global markets where the cold chain elimination would contribute to improving immunization coverage and reducing vaccine wastage



Akston Biosciences Corporation and Biolexis, a division of Stelis Biopharma have entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452, a protein subunit COVID-19 vaccine.

Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-C™) in India and over 130 countries in Asia, Latin America, and Africa largely covering the low-and-middle-income countries (LMICs).

Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships.

AKS-452 or AmbiVax-C™ is a first-of-its-kind thermostable COVID-19 vaccine developed for all parts of the world. AmbiVax-C™ is a SARS-CoV-2 protein subunit vaccine designed to induce a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.

The stability studies conducted on AmbiVax-C™ have demonstrated thermostability at room temperature for over six months at 25° Celsius (77° Fahrenheit) and maintains potency for one month at 37° Celsius (99° Fahrenheit).